您当前的位置：
首页 >
文章列表页 >
Advances in the JAK2/STAT3 signaling pathway and its inhibitors in diffuse large B cell lymphoma
更新时间：2026-03-10

    • Advances in the JAK2/STAT3 signaling pathway and its inhibitors in diffuse large B cell lymphoma

    • “The research progress in the field of DLBCL treatment was introduced, and experts explored the clinical application of JAK2 and STAT3 inhibitors, providing new directions for precision treatment of DLBCL.”
    • ZHONGGUO YAOFANG   Vol. 37, Issue 5, Pages: 682-688(2026)

    • DOI：10.6039/j.issn.1001-0408.2026.05.23    

      CLC： R979.1;R733.4

    • Received：18 August 2025，

      Revised：2026-02-25，

      Accepted：25 February 2026，

      Published：15 March 2026

    移动端阅览

  • LU Chuanyang,CHEN Qiuni,SHI Yuye,et al.Advances in the JAK2/STAT3 signaling pathway and its inhibitors in diffuse large B cell lymphoma[J].ZHONGGUO YAOFANG,2026,37(05):682-688. DOI： 10.6039/j.issn.1001-0408.2026.05.23.

  •  
  •  

0

Views

0

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

No data

Related Author

No data

Related Institution

No data
0